Related Experiment Video
Updated: Mar 8, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.5K
Advances of Coagulation Factor XIII
1Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Chinese Medical Journal
|January 17, 2017
Summary
Coagulation factor XIII (FXIII) is crucial for more than just blood clotting. Its transglutaminase activity supports wound healing, bone health, and pregnancy, with potential roles in diagnosing leukemia and tumors.
Area of Science:
- Biochemistry
- Molecular Biology
- Medical Research
Background:
- Coagulation factor XIII (FXIII) is a transglutaminase enzyme.
- Its role in coagulation is well-established.
- Emerging evidence suggests FXIII involvement in diverse biological processes.
Purpose of the Study:
- To conduct a comprehensive literature review on the multifaceted roles of FXIII.
- To explore FXIII's functions beyond coagulation, including in wound healing, neoplasia, bone metabolism, and pregnancy.
Main Methods:
- Systematic literature search of PubMed (2001-2016) using keywords: "Coagulation factor XIII", "wound", "leukemia", "tumor", "bone", "pregnancy".
- Inclusion of frequently cited pre-2000 publications.
- Review of clinical, animal, and in vitro studies documenting FXIII's biological functions.
Main Results:
- FXIII's transglutaminase activity is vital for wound healing and bone matrix stabilization.
- FXIII plays a role in maintaining healthy pregnancy by influencing embryo-decidua interactions.
- Altered FXIII levels are observed in leukemia and solid tumor patients, suggesting diagnostic potential.
Conclusions:
- FXIII possesses significant biological functions beyond its hemostatic role.
- FXIII's transglutaminase activity is key to wound repair, bone integrity, and successful pregnancy.
- Further investigation is warranted to fully understand FXIII's connection to leukemia and solid tumors.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
432
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
432
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
14.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.4K
01:16Clot Retraction and Fibrinolysis
9.8K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.8K
01:06Coagulation
1.6K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.6K